In Brief: Bayer BAY x1351
Executive Summary
Bayer BAY x1351: Preliminary analysis of data from Phase III trials of the anti-TNF monoclonal antibody does not show superiority to placebo in reducing mortality in septic shock patients. Bayer will await full analyses of the data, which it plans to present in late June and autumn to scientific meetings, before making a decision on continuing development. The company has invested in a $100 mil. biotechnology facility in Berkeley, Calif. to supply the product ("The Pink Sheet" April 14, T&G-5)...